Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

There was no benefit over placebo for resedemtiv in the phase 3 COURAGE-ALS trial on the primary endpoint of change from baseline to 24 weeks in the ALS Functional Rating Scale-Revised (ALSFRS-R ...

CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a placebo.

Clene plans to submit a New Drug Application for CNM-Au8 in ALS by late 2025 and initiate a Phase 3 trial. Clene Inc. announced its plans to submit a New Drug Application (NDA) for CNM-Au8® for ...

for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS ...

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, for a phase 2 clinical trial in ALS.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...